SCHEDULE 13G/A: Blue Owl Capital Holdings LP Discloses 4.2% Passive Stake in Tourmaline Bio, Inc.
Beneficial Ownership Disclosure
Blue Owl Capital Holdings LP has filed an amended Schedule 13G, reporting a 4.2% passive beneficial ownership stake in Tourmaline Bio, Inc. as of December 31, 2024.
Summary
- Blue Owl Capital Holdings LP reported beneficial ownership of 1,079,321 shares of Tourmaline Bio, Inc. common stock.
- This ownership represents 4.2% of Tourmaline Bio, Inc.'s total outstanding common stock.
- The percentage is calculated based on 25,642,610 shares of common stock outstanding as of November 1, 2024, as reported by Tourmaline Bio, Inc. in its quarterly report on Form 10-Q filed on November 7, 2024.
- The filing is an Amendment No. 2 to Schedule 13G, indicating a passive investment position by Blue Owl Capital Holdings LP.
- The Reporting Person certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: Neutral. A Schedule 13G filing is a routine disclosure of passive ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- The disclosure of a 4.2% stake by Blue Owl Capital Holdings LP indicates continued institutional interest in Tourmaline Bio, Inc.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.
Management Comments
- Karen Hager, Chief Compliance Officer of Blue Owl Capital Holdings LP, certified that the information set forth in the statement is true, complete, and correct to the best of her knowledge and belief.
Industry Context
This filing reflects a routine disclosure of a passive investment stake by an institutional investor in a publicly traded biotechnology company. It indicates ongoing institutional interest in the sector, but does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can be a factor in investment decisions.
- Company Management: Informs management of the composition of their shareholder base, particularly the presence of a significant passive investor.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date as of which Tourmaline Bio, Inc. reported 25,642,610 shares of Common Stock outstanding in its Form 10-Q. |
| 2024-11-07 | Date Tourmaline Bio, Inc. filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date for beneficial ownership). |
| 2025-02-14 | Signature date of the Schedule 13G filing by Blue Owl Capital Holdings LP. |
Keywords
Tourmaline Bio, Blue Owl Capital Holdings LP, Schedule 13G, SEC filing, beneficial ownership, common stock, institutional investment, passive stake, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.